Publication
Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerExtraskeletal Myxoid Chondrosarcomacivic_curation1.00
- cancerMesenchymal Chondrosarcomacivic_curation1.00
- drugTrabectedincivic_curation1.00
- geneNCOA2civic_curation1.00
- geneNR4A3civic_curation1.00
- variantNCOA2 Fusioncivic_curation1.00
- variantNR4A3 Fusioncivic_curation1.00
- variantNR4A3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27418251
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NR4A3 Fusion + NR4A3 Fusion1 | ||||||||
| Trabectedin | Extraskeletal Myxoid Chondrosarcoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID12545In a sub-analysis of a randomized phase II trial in extraskeletal myxoid chondrosarcoma (EWSR1-NR4A3 and TAF15-NR4A3 fusions; n = 2) and mesenchymal chondrosarcoma (HEY1-NCOA2 fusion, n = 6)(trabected… (full text at CIViC) PMID 27418251 · Morioka et al., 2016 · Open in CIViC | civic |
| NCOA2 Fusion1 | ||||||||
| Trabectedin | Mesenchymal Chondrosarcoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID12585In a sub-analysis of a randomized phase II trial in extraskeletal myxoid chondrosarcoma (EWSR1-NR4A3 and TAF15-NR4A3 fusions) and mesenchymal chondrosarcoma (HEY1-NCOA2 fusion)(trabectedin n = 5; BSC … (full text at CIViC) PMID 27418251 · Morioka et al., 2016 · Open in CIViC | civic |